Latest Content

Neoadjuvant nivolumab yielded a 68.2% clinical complete response rate in patients with resectable mismatch repair–deficient endometrial cancer.

Patients with metastatic breast cancer achieving a CR/deep PR with frontline T-DXd/pertuzumab had the most durable PFS outcomes in DESTINY-Breast09.

Jonathan Trent, MD, discusses how proactive AE management, dose individualization, and liquid TKI formulations could improve treatment adherence and outcomes in GIST.

Starting TTFields with chemoradiotherapy did not significantly improve OS vs using TTFields in the maintenance phase in newly diagnosed glioblastoma.

The CDK4/6 inhibitor and aromatase inhibitor combination produced a 32% ORR and 48% clinical benefit rate at 6 months.

Phase 1 data show that BGB-16673 is eliminated through intestinal and biliary excretion, limiting CYP3A-mediated interactions.

Despite a higher response rate with the combination, the phase 2 MIROVA/AGO-OVAR 2.34 trial did not meet its primary PFS end point over chemotherapy.

Updated data from the phase 2 COLIBRI-1 trial suggest that immune microenvironment status at baseline and following ICB induction may predict long-term survival.

The FDA has accepted a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in R/R LBCL.

Lung cancer experts convened at an OncLive® Scientific Interchange and Workshop to discuss treatment sequencing in HER2+ NSCLC.

Real-world data showed zanubrutinib was associated with longer time to treatment discontinuation and higher persistence vs acalabrutinib or ibrutinib in first-line CLL.

Trastuzumab pamirtecan produced durable responses and encouraging survival in HER2-expressing endometrial cancer after prior therapy.

The B7-H4–targeted antibody-drug conjugate produced confirmed response rates of 62% in PROC and 67% in endometrial cancer at the doses selected for phase 3 development.